Literature DB >> 15309734

Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.

Shu-Qiang Yue1, Yan-Ling Yang, Jing-Shi Zhou, Kai-Zong Li, Ke-Feng Dou.   

Abstract

AIM: To investigate the relationship of urokinase type plasminogen activator receptor (uPAR) and vascular endothelial growth factor (VEGF) expression with clinical and pathological characteristics of human gallbladder cancer.
METHODS: uPAR and VEGF expressions in 68 gallbladder cancer tissues were detected with anti-receptor immunohistochemical stain.
RESULTS: Expression rate of uPAR was 57.4% (39/68), and VEGF 51.5% (35/68) in gallbladder cancer tissues. Expression of both uPAR and VEGF was significantly related to metastasis, but not significantly correlated with differentiation stage and size of gallbladder cancer.
CONCLUSION: Expression of uPAR and VEGF may be an invasive phenotype of gallbladder cancer and indicator for predicting prognoses, and uPAR expression is significantly correlated with the expression of VEGF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15309734      PMCID: PMC4572208          DOI: 10.3748/wjg.v10.i18.2750

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  40 in total

Review 1.  The plasminogen activation system in tumor growth, invasion, and metastasis.

Authors:  P A Andreasen; R Egelund; H H Petersen
Journal:  Cell Mol Life Sci       Date:  2000-01-20       Impact factor: 9.261

2.  Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

Authors:  Volker Viereck; Carsten Gründker; Sabine Blaschke; Britta Niederkleine; Heide Siggelkow; Karl-Heinz Frosch; Dirk Raddatz; Günter Emons; Lorenz C Hofbauer
Journal:  J Clin Endocrinol Metab       Date:  2003-09       Impact factor: 5.958

3.  Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.

Authors:  Laurent Ramont; Sylvie Pasco; William Hornebeck; François-Xavier Maquart; Jean Claude Monboisse
Journal:  Exp Cell Res       Date:  2003-11-15       Impact factor: 3.905

4.  The role of plasminogen in angiogenesis in vivo.

Authors:  C-W Oh; J Hoover-Plow; E F Plow
Journal:  J Thromb Haemost       Date:  2003-08       Impact factor: 5.824

5.  A high cytosol value of urokinase-type plasminogen activator (uPA) may be predictive of early relapse in primary breast cancer.

Authors:  Claudio Dazzi; Anna Cariello; Patrizia Maioli; Serena Magi; Giovanni Rosti; Petros Giovanis; Gloria Giovannini; Giuseppe Lanzanova; Maurizio Marangolo
Journal:  Cancer Invest       Date:  2003-04       Impact factor: 2.176

6.  Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells.

Authors:  Alice Hemsen; Lutz Riethdorf; Nils Brünner; Jürgen Berger; Sebastian Ebel; Christoph Thomssen; Fritz Jänicke; Klaus Pantel
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

Review 7.  Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.

Authors:  Zhenping Zhu; Peter Bohlen; Larry Witte
Journal:  Curr Cancer Drug Targets       Date:  2002-06       Impact factor: 3.428

8.  Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention.

Authors:  S Braun; N Harbeck
Journal:  Expert Rev Mol Med       Date:  2001-09-06       Impact factor: 5.600

9.  Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer.

Authors:  Shashi R Harvey; Thelma C Hurd; Gabor Markus; Maisie I Martinick; Remedios M Penetrante; Dongfeng Tan; Preeti Venkataraman; Nisha DeSouza; Sheila N J Sait; Deborah L Driscoll; John F Gibbs
Journal:  Clin Cancer Res       Date:  2003-10-15       Impact factor: 12.531

10.  Higher susceptibility to Fas ligand induced apoptosis and altered modulation of cell death by tumor necrosis factor-alpha in periarticular tenocytes from patients with knee joint osteoarthritis.

Authors:  Andreas Machner; Anja Baier; Aline Wille; Susanne Drynda; Géza Pap; Andreas Drynda; Christian Mawrin; Frank Bühling; Steffen Gay; Wolfram Neumann; Thomas Pap
Journal:  Arthritis Res Ther       Date:  2003-06-30       Impact factor: 5.156

View more
  5 in total

1.  Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas.

Authors:  Toshiyuki Nakayama; Yang-Cheul Cho; Yuka Mine; Ayumi Yoshizaki; Shinji Naito; Chun-Yang Wen; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 2.  Anti-angiogenic strategies in gastrointestinal malignancies.

Authors:  Jonathan Whisenant; Emily Bergsland
Journal:  Curr Treat Options Oncol       Date:  2005-09

3.  Expression of epidermal growth factor receptor, p53, Bcl2, vascular endothelial growth factor, cyclooxygenase-2, cyclin D1, human epidermal receptor-2 and Ki-67: Association with clinicopathological profiles and outcomes in gallbladder carcinoma.

Authors:  Dinesh Chandra Doval; Saud Azam; Rupal Sinha; Ullas Batra; Anurag Mehta
Journal:  J Carcinog       Date:  2014-08-25

4.  Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.

Authors:  Sven H Loosen; Annemarie Breuer; Frank Tacke; Jakob N Kather; Joao Gorgulho; Patrick H Alizai; Jan Bednarsch; Anjali A Roeth; Georg Lurje; Sophia M Schmitz; Jonathan F Brozat; Pia Paffenholz; Mihael Vucur; Thomas Ritz; Alexander Koch; Christian Trautwein; Tom F Ulmer; Christoph Roderburg; Thomas Longerich; Ulf P Neumann; Tom Luedde
Journal:  JHEP Rep       Date:  2020-01-31

5.  Remarkable Response of Metastatic Gallbladder Carcinoma to Apatinib After Failed Multiline Chemotherapies: A Case Report and Literature Review.

Authors:  Mengxi Zhang; Pengfei Zhang; Kexun Zhou; Qiu Li
Journal:  Front Oncol       Date:  2019-11-08       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.